News
One year round up – what we’ve been up to in our first year
The 1st September 2019 officially marks the one year anniversary of the launch of TherapeutAix – and what an exciting year it’s been! To celebrate
International NASH Day 2019
On International NASH Day 2019 we discuss the mixed outcomes of NASH drug clinical trials and how we believe a platform of evidence can be
TherapeutAix adds Immunoconsulting to global R&D Network
We are pleased to announce that we have grown our global R&D Network with the addition of ImmunoConsulting Ltd. ImmunoConsulting, a consulting business that provides
Recent study highlights the challenges in developing treatments for NASH
We previously commented on the failure of the ASK-1 inhibitor, selonsertib, in the STELLAR-4 phase III study in patients with compensated cirrhosis (F4) due to NASH.
TherapeutAix/Medicines Discovery Catapult session on drug discovery in fibrotic disease at the BOS Basel event in Switzerland
BOS (Biotech Outsourcing Strategies) Basel 2019 will bring together stakeholders in pharmaceutical R&D outsourcing, who share knowledge, develop skills and build new and existing relationships
TherapeutAix NASH review article is now available online!
At the end of last year, TherapeutAix published an article titled ‘The future R&D landscape in non-alcoholic steatohepatitis’ in Drug Discovery Today. The review aims
TherapeutAix is speaking at the 18th Fraunhofer Seminar “Models of Lung Disease”
Darcey Black, Translational Director of TherapeutAix, will be speaking at the 18th Fraunhofer Seminar titled “Models of Lung Disease” on Friday 25th of January. Held